Literature DB >> 28405956

The impact of polypharmacy and drug interactions among the elderly population in Western Sicily, Italy.

Giulia Scondotto1, Fanny Pojero1, Sebastiano Pollina Addario2, Mauro Ferrante3, Maurizio Pastorello4, Michele Visconti4, Salvatore Scondotto2, Alessandra Casuccio5.   

Abstract

AIM: Primary endpoint was to report polypharmacy distribution in the general population vs ≥65 years old people and to examine the frequency of drug-drug interactions (DDIs) in the Health Local Unit of Palermo, Italy, in relationship with patients' age.
METHODS: Drug prescription data for the year 2014 were extracted from the database of the Local Health Unit of Palermo Province, Italy. Patients were divided into five age groups (0-13, 14-64, 65-69, 70-74, and ≥75 year old). The detection of potential DDIs in polypharmacy profiles was performed with NavFarma software (Infologic srl, Padova, Italia), with DDI classification provided by tool Micromedex Drug Reax (Truven Health Analitics, Michigan, USA).
RESULTS: We analyzed data of 1,324,641 patients, and 15,801,191 medical prescription were recorded; of these, 11,337,796 regarded chronic conditions. The drug prescriptions reached the highest values in the 65-69 and 70-74 age groups (p = 0.005 and p = 0.008 vs age 14-64 respectively). An overall amount of 6,094,373 DDIs were detected, of which 47,173 were contraindicated. Median number of DDIs was higher in 65-69 and 70-74 age groups (p = 0.008 and p = 0.012 vs age 14-64, respectively). Regarding contraindicated DDIs a significant difference was detected comparing 14-64 vs ≥65 age groups (p = 0.010 vs 65-69 group, p = 0.005 vs 70-74 group and ≥75 group).
CONCLUSIONS: Polypharmacy is a phenomenon acquiring increasing dimensions also in our province. It interests particularly the older subjects, and assumes a dramatic accent when it is put in relationship with the frequency of DDIs. A proactive vigilance about potential life threatening drug interactions is mandatory.

Entities:  

Keywords:  Contraindicated drug–drug interactions; Drug interactions; Drug prescriptions; Elderly population; Polypharmacy

Mesh:

Year:  2017        PMID: 28405956     DOI: 10.1007/s40520-017-0755-2

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   3.636


  6 in total

Review 1.  Drug-Induced Kidney Injury in the Elderly.

Authors:  Sana Khan; Valentina Loi; Mitchell H Rosner
Journal:  Drugs Aging       Date:  2017-10       Impact factor: 3.923

2.  The appropriateness of antiplatelet and anticoagulant drug prescriptions in hospitalized patients in an internal medicine ward.

Authors:  Marta Manzocco; Alessandro Delitala; Sara Serdino; Roberto Manetti; Angelo Scuteri
Journal:  Aging Clin Exp Res       Date:  2019-10-30       Impact factor: 3.636

3.  Prevalence and Age Structure of Polypharmacy in Poland: Results of the Analysis of the National Real-World Database of 38 Million Citizens.

Authors:  Przemysław Kardas; Filip Urbański; Aneta Lichwierowicz; Ewa Chudzyńska; Grzegorz Kardas; Marcin Czech
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

4.  Adverse drug reactions and correlations with drug-drug interactions: A retrospective study of reports from 2011 to 2020.

Authors:  Huaqiao Jiang; Yanhua Lin; Weifang Ren; Zhonghong Fang; Yujuan Liu; Xiaofang Tan; Xiaoqun Lv; Ning Zhang
Journal:  Front Pharmacol       Date:  2022-08-22       Impact factor: 5.988

5.  Blood pressure and hypertension prevalence among oldest-old in China for 16 year: based on CLHLS.

Authors:  Jiajun Du; Guoning Zhu; Yanhong Yue; Miao Liu; Yao He
Journal:  BMC Geriatr       Date:  2019-09-09       Impact factor: 3.921

6.  Physical Performance and Quality of Life in Older Adults: Is There Any Association between Them and Potential Drug Interactions in Polymedicated Octogenarians.

Authors:  Zoraida Verde; Laura García de Diego; Luis M Chicharro; Fernando Bandrés; Verónica Velasco; Teresa Mingo; Ana Fernández-Araque
Journal:  Int J Environ Res Public Health       Date:  2019-10-29       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.